{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:56Z","timestamp":1792699976926,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s13318-018-0526-2","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T16:27:03Z","timestamp":1541089623000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-6530","authenticated-orcid":false,"given":"Dario","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"526_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/505147","volume":"194","author":"RP Walensky","year":"2006","unstructured":"Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11\u20139.","journal-title":"J Infect Dis"},{"key":"526_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/aje\/kws321","volume":"177","author":"N Wada","year":"2013","unstructured":"Wada N, Jacobson LP, Cohen M, French A, Phair J, Mu\u00f1oz A. Cause-specific life expectancies after 35\u00a0years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984\u20132008. Am J Epidemiol. 2013;177:116\u201325.","journal-title":"Am J Epidemiol"},{"key":"526_CR3","first-page":"83","volume":"20","author":"H Joulaei","year":"2018","unstructured":"Joulaei H, Shooshtarian S, Dianatinasab M. Is UNAIDS 90-90-90 target a dream or a reality for Middle East and North Africa region on ending the AIDS epidemic? A review study. AIDS Rev. 2018;20:83\u201393.","journal-title":"AIDS Rev"},{"key":"526_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/COH.0000000000000219","volume":"11","author":"RJ Landovitz","year":"2016","unstructured":"Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016;11:122\u20138.","journal-title":"Curr Opin HIV AIDS"},{"key":"526_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/COH.0000000000000002","volume":"8","author":"WR Spreen","year":"2013","unstructured":"Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8:565\u201371.","journal-title":"Curr Opin HIV AIDS"},{"key":"526_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","volume":"103","author":"A Owen","year":"2016","unstructured":"Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016;103:144\u201356.","journal-title":"Adv Drug Deliv Rev"},{"key":"526_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/13543784.2018.1460357","volume":"27","author":"TD McPherson","year":"2018","unstructured":"McPherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. Expert Opin Investig Drugs. 2018;27:413\u201320.","journal-title":"Expert Opin Investig Drugs"},{"key":"526_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/COH.0000000000000161","volume":"10","author":"CD Andrews","year":"2015","unstructured":"Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Curr Opin HIV AIDS. 2015;10:258\u201363.","journal-title":"Curr Opin HIV AIDS"},{"key":"526_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10:239\u201345.","journal-title":"Curr Opin HIV AIDS"},{"key":"526_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/00498254.2015.1060372","volume":"46","author":"GD Bowers","year":"2016","unstructured":"Bowers GD, Culp A, Reese MJ, Tabolt G, Moss L, Piscitelli S, Huynh P, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46:147\u201362.","journal-title":"Xenobiotica"},{"key":"526_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2017.10.017","volume":"268","author":"BM Jucker","year":"2017","unstructured":"Jucker BM, Alsaid H, Rambo M, Lenhard SC, Hoang B, Xie F, et al. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat. J Control Release. 2017;268:102\u201312.","journal-title":"J Control Release"},{"key":"526_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1126\/science.1248707","volume":"343","author":"CD Andrews","year":"2014","unstructured":"Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus. Science. 2014;343:1151\u20134.","journal-title":"Science"},{"key":"526_CR13","doi-asserted-by":"publisher","first-page":"270ra4","DOI":"10.1126\/scitranslmed.3010298","volume":"7","author":"CD Andrews","year":"2015","unstructured":"Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, Gettie A, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7:270ra4.","journal-title":"Sci Transl Med"},{"key":"526_CR14","doi-asserted-by":"publisher","first-page":"270ra5","DOI":"10.1126\/scitranslmed.3010297","volume":"7","author":"J Radzio","year":"2015","unstructured":"Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, Garc\u00eda-Lerma JG, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7:270ra5.","journal-title":"Sci Transl Med"},{"key":"526_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1310\/hct1405-192","volume":"14","author":"W Spreen","year":"2013","unstructured":"Spreen W, Min S, Ford SL, Chen S, Lou Y, Bomar M, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14:192\u2013203.","journal-title":"HIV Clin Trials"},{"key":"526_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Ford SL, Chen S, Wilfret D, Margolis D, Gould E, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67:481\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"526_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"526_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499\u2013510.","journal-title":"Lancet"},{"key":"526_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40262-017-0557-x","volume":"57","author":"RKR Rajoli","year":"2018","unstructured":"Rajoli RKR, Back DJ, Rannard S, Meyers CF, Flexner C, Owen A, et al. In silico dose prediction for long-acting rilpivirine and cabotegravir administration to children and adolescents. Clin Pharmacokinet. 2018;57:255\u201366.","journal-title":"Clin Pharmacokinet"},{"key":"526_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40262-016-0424-1","volume":"56","author":"AT Podany","year":"2017","unstructured":"Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56:25\u201340.","journal-title":"Clin Pharmacokinet"},{"key":"526_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1586\/14787210.2015.1075393","volume":"13","author":"TE Park","year":"2015","unstructured":"Park TE, Mohamed A, Kalabalik J, Sharma R. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther. 2015;13:1195\u2013212.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"526_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/AAC.03909-14","volume":"59","author":"T Yoshinaga","year":"2015","unstructured":"Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59:397\u2013406.","journal-title":"Antimicrob Agents Chemother"},{"key":"526_CR23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001726","volume":"32","author":"U Neogi","year":"2018","unstructured":"Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32:469\u201376.","journal-title":"AIDS"},{"key":"526_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cpdd.272","volume":"5","author":"Y Lou","year":"2016","unstructured":"Lou Y, Buchanan AM, Chen S, Ford SL, Gould E, Margolis D, et al. Effect of cabotegravir on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:509\u201316.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"526_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/00498254.2015.1081993","volume":"46","author":"MJ Reese","year":"2016","unstructured":"Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46:445\u201356.","journal-title":"Xenobiotica"},{"key":"526_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/AAC.01685-12","volume":"57","author":"SL Ford","year":"2013","unstructured":"Ford SL, Gould E, Chen S, Lou Y, Dumont E, Spreen W, et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S\/GSK1265744. Antimicrob Agents Chemother. 2013;57:277\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"526_CR27","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1128\/AAC.01235-13","volume":"57","author":"SL Ford","year":"2013","unstructured":"Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57:5472\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"526_CR28","doi-asserted-by":"publisher","first-page":"e00487","DOI":"10.1128\/AAC.00487-17","volume":"61","author":"SL Ford","year":"2017","unstructured":"Ford SL, Sutton K, Lou Y, Zhang Z, Tenorio A, Trezza C, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61:e00487\u2013517.","journal-title":"Antimicrob Agents Chemother"},{"key":"526_CR29","doi-asserted-by":"crossref","unstructured":"Ford S, Lou Y, Lewis N, D\u2019Amico R, Spreen W, Patel P. Rifabutin (RBT) decreases cabotegravir (CAB) exposure following oral co-administration. In: 19th International Workshop on Clinical Pharmacology. Baltimore. 22\u201324 May 2018. Oral abstract 12.","DOI":"10.3851\/IMP3306"},{"key":"526_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/bcp.13236","volume":"83","author":"C Trezza","year":"2017","unstructured":"Trezza C, Ford SL, Gould E, Lou Y, Huang C, Ritter JM, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel\/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83:1499\u2013505.","journal-title":"Br J Clin Pharmacol"},{"key":"526_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/QAD.0000000000001343","volume":"31","author":"CD Andrews","year":"2017","unstructured":"Andrews CD, Bernard LS, Poon AY, Mohri H, Gettie N, Spreen WR, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017;31:461\u20137.","journal-title":"AIDS"},{"key":"526_CR32","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331\u201340.","journal-title":"Lancet HIV"},{"key":"526_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/infdis\/jiv528","volume":"213","author":"KJ Penrose","year":"2016","unstructured":"Penrose KJ, Parikh UM, Hamanishi KA, Else L, Back D, Boffito M, et al. Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA). J Infect Dis. 2016;213:1013\u20137.","journal-title":"J Infect Dis"},{"key":"526_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018;151:53\u201365.","journal-title":"Biomaterials"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0526-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T01:45:13Z","timestamp":1662342313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0526-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0526-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"1 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to write this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest with any person or financial and institutional body.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}